http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2910165-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd5537af900106df1a2e4d63470098e3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-207 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7064 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 |
| filingDate | 2018-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ca6108ba88cec382710e7db3792e73c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b40346394bc01b868e2455d92326d31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f4bed309e6f08b1ad4c4266224125cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9241351de8feae5b3d679fb1cac602c0 |
| publicationDate | 2022-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2910165-T3 |
| titleOfInvention | Nucleoside diphosphate phosphoramidate salts as anticancer compounds |
| abstract | A compound of formula (I), or a pharmaceutically acceptable salt thereof: **(See formula)** wherein R1 is independently selected at each occurrence from: C1-C24 alkyl, C3-C24 alkenyl, C3- C24, C0-C4 alkylene-C3-C8 cycloalkyl and C0-C4 alkylene-aryl; R2 and R3 each independently at each occurrence are selected from H, C1-C6 alkyl, and C1-C3-R7 alkylene; or R2 and R3 together with the atom to which they are attached form a 3 to 6 membered cycloalkyl or heterocycloalkyl group; R4 is independently at each occurrence H or C1-C4 alkyl; or R4, a group selected from R2 and R3 and the atoms to which they are attached may form a 3 to 6 membered heterocycloalkyl group; R5 is independently selected at each occurrence from aryl, 5-, 6-, 9- or 10-membered heteroaryl, C3-C8 cycloalkyl, 3-7 membered heterocycloalkyl, C1-C3-R5a alkylene and C1-C8 alkyl, said aryl is optionally fused a C6-C8 cycloalkyl; R5a is independently selected at each occurrence from aryl, 5-, 6-, 9- or 10-membered heteroaryl, C3-C8 cycloalkyl, 3-7 membered heterocycloalkyl, which aryl is optionally fused to C6-C8 cycloalkyl; R6 is independently selected from: **(See formula)** and **(See formula)** R7 is independently selected at each occurrence of aryl, imidazole, indole, SRa, ORa, CO2Ra, CO2NRaRa, NRaRb and NH(= NH)NH2; R8 is independently selected from H and **(See formula)** Z1 and Z2 are each independently selected from O and S; Y is independently selected from H, F, Cl and OMe; X is independently at each occurrence a pharmaceutically acceptable cation; wherein any aryl group is either phenyl or naphthyl; wherein when any of R1, R2, R3, R4, R5, or R7 is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, that alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally substituted with from 1 to 4 selected substituents from: halo, nitro, cyano, NRaRa, NRaS(O)2Ra, NRaC(O)Ra, NRaCONRaRa, NRaCO2Ra, ORa; SRa, SORa, SO3Ra, SO2Ra, SO2NRaRa, CO2Ra, C(O)Ra, CONRaRa, CRaRaNRaRa, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, and C1-C4 haloalkyl; wherein Ra is independently selected at each occurrence from: H and C1-C4 alkyl; and Rb is independently selected at each occurrence from: H, and C1-C4 alkyl and C(O)-C1-C4 alkyl. |
| priorityDate | 2017-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415968536 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID448310 |
Total number of triples: 28.